Macrovascular and microvascular complications in type 2 diabetic Iraqi patients treated by metformin and glibenclamide versus metformin and sitagliptin

this article has been read 182 times    0 user(s) have rated this article

Author: administrator

26/5/2014 9:23 AM

Macrovascular and microvascular complications in type 2 diabetic Iraqi patients treated by metformin and glibenclamide versus metformin and sitagliptin



Hassan M. Abbas Al-Temimi, PhD*
Kassim J. Al-Shamaa, PhD**
Salim Al-Rubai, PhD***
* Clinical pharmacist,Medical City, Ministry of Health , Iraq
** Pharmacologist, College of Pharmacy, University of Baghdad
*** Assistant Professor, endocrinologist, College of Medicine,University of Baghdad


Abstract:

Background: In type 2 diabetes mellitus there is a progressive loss of beta cell function. One new approach yielding promising results is the use of the orally active dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus.
Objective: This study aims at comparing the possible occurrence of macrovascular & microvascular complications in Iraqis patients with type 2 diabetes mellitus using two combinations of drugs metformin + glibenclamide and metformin + sitagliptin.
Methodology: Sixty eight T2DM patients and 34 normal healthy individuals as control group were enrolled in this study and categorized in to two treatment groups. The group 1 (34 patients ) received metformin 500 mg three times daily + glibenclamide 5 mg twice daily and the group 2 (34 patients) received metformin 500 mg three times daily + sitagliptin 100 mg once daily. The urine sample was collected for estimation of microalbumin urea and patients' examination was made by specialist consultant endocrinologist.




Download File




   

More News





Readers Comments



Site Search

Custom Google Search

Journals

Visitors

Last Updated

Picture Gallery